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In this study, Lactobacillus pentosus expressing porcine lactoferrin (pLF) 
was tested for in vitro antibacterial activity and for its ability to enhance immunity 
induced by an orally administered Aujeszky’s disease virus (ADV) vaccine. The 
cDNA encoding N-terminus of pLF was cloned into a Lactobacillus-specific 
plasmid to produce L. pentosus pLF expressing transformants (pPG612.1-pLF-
N/L. pentosus). The antimicrobial activity of the recombinant pLF protein inhib-
ited bacterial growth in vitro. The supernatant of pPG612.1-pLF-N/L. pentosus 
had an inhibitory effect on Staphylococcus aureus strain CVCC26003, Bacillus 
subtilis strain CVCC63501, Escherichia coli strain CVCC10141 and Salmonella 
enterica ssp. enterica Choleraesuis strain CVCC79102, while it did not inhibit the 
growth of Lactobacillus casei strain ATCC393. A mouse model was established 
to test the effectiveness of the orally administered probiotic L. pentosus recombi-
nant strain in the gastrointestinal tract. Mice were immunised with an attenuated 
porcine Aujeszky’s disease virus (ADV) vaccine. Serum antibody levels deter-
mined using a mouse Aujeszky’s disease IgG ELISA showed that IgG levels were 
significantly higher in the pPG612.1-pLFN/L. pentosus group than in the PBS and 
Lactobacillus pentosus groups at days 7 and 21 (P < 0.01) and at day 14 (P < 
0.05), indicating that this oral recombinant strain can improve the effectiveness of 
the vaccine and play a role in immune enhancement through humoral immunity. 
These results suggest that the recombinant Lactobacillus pentosus not only has 
the beneficial characteristics of lactic acid bacteria but also produces biologically 
functional lactoferrin.  
Key words: Porcine lactoferrin, recombinant Lactobacillus pentosus, anti-
bacterial activity, immune enhancement 
Lactoferrin (LF) is an 80-kDa iron-binding glycoprotein. It is abundantly 
found in exocrine secretions of mammals and especially in milk and fluids of the 
digestive tract released by mucosal epithelia and neutrophils during inflamma-
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tion (Naot et al., 2005; Bhatia, 2011). It is well known that LF exerts a direct an-
timicrobial effect at the surface epithelia by killing microbes or inhibiting their 
proliferation and adhesion (Puddu et al., 2011). The antimicrobial properties of 
LF are mainly related to its ability to bind with iron in biological fluids to dam-
age the membranes of microorganisms. However, iron-independent microbicidal 
activities require a direct interaction between LF and microbial surface compo-
nents (Miller et al., 2008). In addition to the antimicrobial properties of LF, its 
ability to modulate the overall immune response and to elevate immunity against 
viral infections has been largely described (Wolf et al., 2007; Actor et al., 2009; 
Ishikawa et al., 2013). In this respect, it is noteworthy that LF can promote the 
recruitment and activation of antigen-presenting cells and the antigen-specific 
immune response (de la Rosa et al., 2008). 
Due to its extensive biological activity, LF is widely used in high-
efficiency iron supplements, feed additives, immune modulators, antioxidants 
and other agents. However, the traditional separation and purification of LF from 
the colostrum is a cumbersome process; therefore, the use of genetic engineering 
methods to produce recombinant LF has become a main focus of this technology 
(Wang et al., 1997; Wang et al., 2002; Pecorini et al., 2005; Chen et al., 2008). In 
genetically engineered cells, whether they are bacterial, yeast or animal cells, the 
expression and collection of exogenous protein usually require purification 
(Garcia-Montoya et al., 2013). The tedious purification process has been a bar-
rier to applying genetically engineered cells in production. 
LF does not inhibit the low iron demand of lactic acid bacteria and it can 
also promote the growth of beneficial bacteria such as bifidobacteria and lacto-
bacilli in the gut of animals. Many studies have shown that the use of the probi-
otic Lactobacillus as a vector delivery system has unmatched superiority com-
pared to other known eukaryotes and prokaryotes (Wyszynska et al., 2015). In 
this research, using lactating porcine mammary tissue RNA as a template to ob-
tain the N terminus pLF gene, we successfully obtained recombinant lactic acid 
bacteria expressing the pLF gene. Furthermore, we studied the antibacterial ac-
tivity of Lactobacillus pentosus expressing porcine lactoferrin against different 
bacteria and its effects on immunity induced by ADV vaccine in a mouse model. 
 
 
Materials and methods 
Construction of recombinant pPG612-pLFN/Lactobacillus pentosus 
The DNA insert containing codon-optimised pLF-N gene (1038 bp of the 
5’ terminus of porcine lactoferrin nucleotide) was synthesised by Sangon Biotech 
Co. Ltd. (Shanghai, China). The synthetic fragment was digested with BamHI and 
XhoI restriction enzymes and cloned into the plasmid vector pPG612.1. Cloning 
of the pPG612.1-pLF-N expression construct was performed as described in Mo-
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lecular Cloning: A Laboratory Manual (Sambrook and Russell, 2001). A pair of 
primers was designed to identify the recombinant plasmid containing the pLF 
sequence: forward (5’-GGATCCAATGAAACTGTTTATTCCG-3’) and reverse 
(5’-CTCGAGCAGGCCCTGAATGGCGGT-3’). The optimised pLF insert was 
subsequently cloned into the multiple cloning site (MCS) of a 5174-bp expres-
sion vector pPG612.1 (Lactrys, Denmark) that was linearised with BamHI and 
XhoI. The resultant construct known as pPG612.1-pLF-N (Fig. 1) contains the 
xylose operon promoter, a secretion signal peptide USP45, a repA replicon, and 
a chloramphenicol resistance (Cmr) gene for selection. The expression construct 
was then transformed into Lactobacillus pentosus (KLDS1.0413 strain, from Key 
Lab of Dairy Science, Ministry of Education, Harbin, China) competent cells via 
electroporation. DNA sequencing confirmed the identity of the plasmid. The 
original pPG612.1 vector without the pLF-N insert was also transformed into L. 
pentosus to serve as control. The operations described in this section were per-
formed as described by Zong et al. (2011). The recombinant strains were named 
pPG612.1-pLF-N/L. pentosus and pPG612.1/L. pentosus, respectively. 
 
Fig. 1. Map of pPG612-pLF-N. Cmr resistance determinant, repA and repC replication elements, 
xylP promoter and multiple cloning sites are shown. The signal sequence is translationally fused to 
the xylP promoter. The pLF-N gene was obtained from mammary gland tissue of a lactating sow 
on the third day of lactation by RT-PCR and then, according to the codon bias of Lactobacillus,  
the porcine lactoferrin N gene was codon-optimised and synthesised 
Protein expression and localisation analysis 
To analyse the expression and localisation of the pLF-N fusion protein by 
xylose induction, cultures of strains pPG612.1-pLF-N/L. pentosus and pPG612.1/ 
L. pentosus were grown overnight in basal MRS medium supplemented with xy-
lose to induce the expression of the recombinant protein and then collected by 
centrifugation at 12,000 g for 10 min. The pellets were washed twice with sterile 
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by vigorous shaking. The lysates were centrifuged at 15,000 g for 10 min and the 
supernatants were examined using 12% sodium dodecyl sulphate–polyacrylamide 
gel electrophoresis (SDS-PAGE). Proteins were electro-transferred onto a nitro-
cellulose membrane and the immunoblots were developed using rabbit anti-pLF-
N serum at a dilution of 1:500 with phosphate-buffered saline (PBS). Horserad-
ish peroxidase- (HRP-) conjugated goat anti-rabbit IgG (Sigma-Aldrich Co, St. 
Louis, MO, USA) diluted at 1:2000 was used and the immunolabelled bands 
were then visualised using the Chemiluminescent Substrate reagent (Pierce™, 
Thermo Fisher Scientific Inc, Waltham, MA, USA) according to the manufac-
turer’s instructions. 
Enzyme-linked immunosorbent assay (ELISA) was used to analyse the se-
creted protein from the recombinant L. pentosus. The induced (+) and non-
induced (–) supernatants of pPG612.1-pLF-N/L. pentosus were collected by cen-
trifugation. Polystyrene microtitre plates were coated overnight at 4 °C either 
with the supernatant of pPG612.1-pLF-N/L. pentosus or with supernatants har-
vested from pPG612.1/L. pentosus as negative control. ELISA plates were 
washed three times with PBS containing 1% Tween 20 and then blocked with 
PBS containing 5% skim milk for 2 h. Rabbit anti-pLF sera (produced and stored 
in our laboratory) were serially diluted in PBS 1% BSA and incubated at 37 °C 
for 1 h, washed three times and then incubated with a 1:2000 dilution (100 µL) 
of an HRP-conjugated goat anti-rabbit IgG (Sigma-Aldrich Co, St. Louis, MO, 
USA), washed and visualised following the addition of 100 μl of o-phenylenedia-
mine dihydrochloride substrate (Sigma-Aldrich Co, St. Louis, MO, USA). The 
absorbance was measured at 490 nm. 
In vitro antibacterial activity assays 
Determination of the bacterial inhibition curve of the recombinant pLF 
protein produced from L. pentosus transformant was performed using a standard 
protocol with an inoculum of 1 × 103 bacteria colony-forming units per ml in 
MRS medium (for lactobacillus) or Luria-Bertani medium (for other tested bac-
teria), as described earlier (Chen et al., 2004). The tested bacteria include Staphy-
lococcus aureus strain CVCC26003, Bacillus subtilis strain CVCC63501, Es-
cherichia coli strain CVCC10141, Salmonella enterica ssp. enterica Cholerae-
suis strain CVCC79102 and Lactobacillus casei strain ATCC393. 
Determination of the effect of pLF-N on the immune response  
In order to assess the immune-modulating effects of recombinant pLF-N 
protein and to determine whether it can enhance the immunising effect of vac-
cines, we used a mouse model to study immunity against ADV virus infection. 
A commercial attenuated porcine Aujeszky’s disease virus vaccine (China 
Animal Husbandry Industry Company Ltd., China) was inoculated into 6–8 
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weeks old BALB/c mice (purchased from Harbin Veterinary Research Institute) 
housed in individual ventilation cages (IVCs; temperature, 32.70 ± 2.99 °C; rela-
tive humidity, 77.54 ± 2.34%; THI, temperature-humidity index, 87.27) and fed 
ad libitum. The mice (n = 120) were maintained under specific pathogen free 
conditions and received a sterile rodent food and water ad libitum. The experi-
ment was approved by the Animal Research and Care Committee of Northeast 
Agricultural University, China. The mice were divided into three (PBS, L. pento-
sus and L. pentosus/pPG612.1-pLF-N) groups of 10 animals each. They were fed 
2 × 109 cfu of the recombinant strain or L. pentosus for 21 days. Twelve ran-
domly selected mice from each treatment (4 mice per treatment) were anaesthe-
tised by isoflurane inhalation and blood samples were collected from their tail 
vein. Sera were collected at days 0, 7, 14, 21, 28, 35 and 42. Serum antibody lev-
els were determined using an ADV IgG Elisa kit (The GreenSpring TM Porcine 
Pseudorabies ELISA Test Kit, Shenzhen Lvshiyuan Biotechnology Co. Ltd., 
China) according to the manufacturer’s instructions. 
Statistical analysis 
The SPSS Statistics v17.0 software (International Business Machines Cor-
poration, New York, USA) was used for single-factor analysis of variance. The 
differences between groups with probability values of less than 0.05 were con-




pPG612-pLF-N/L. pentosus colonies were grown overnight in basal MRS 
medium (without glucose, and substituted by xylose). The cell lysates were ana-
lysed by SDS-PAGE and Western blot using rabbit anti-pLF serum. Coomassie 
blue gel staining showed an approximately 45 kDa fusion protein band in pPG612-
pLF-N/L. pentosus (Fig. 2, lane 2) but not in L. pentosus KLDS1.0413 with 
pPG612.1 (Fig. 2, lane 1) or wild-type L. pentosus KLDS1.0413 (data not shown). 
Similarly, an immunoreactive band was detected (Fig. 3, lane 2) by Western blot 
in a similar position as observed in the SDS-PAGE in pPG612-pLF-N/L. pentosus 
(Fig. 2, lane 2). As negative control, L. pentosus KLDS1.0413 with pPG612.1 
did not display the corresponding immunoreactive band (Fig. 3, lane 1). These 
results show that the xylP promoter from pPG612.1 could efficiently induce the 
expression of the pLF heterologous protein. 
The indirect ELISA assay was developed with mouse anti-PLF serum and 
HRP-conjugated goat anti-mouse IgG to confirm the presence of cell-secreted 
pLF-N protein. The results indicated that pLF-N protein was present in the su-
pernatant of overnight culture while it was absent from the control bacteria (Fig. 4). 
The results of localisation analysis suggested that the pLF-N protein could be se-
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creted by the signal peptide of the expression vector plasmid. The recombinant 
protein could be detected in both the culture supernatant and intracellularly. 
 
Fig. 2. Identification of the protein expressed in Lactobacillus pentosus by Coomassie blue gel 
staining. Lane 1: pPG612.1/L. pentosus induced by xylose; lane 2: recombinant strain pPG612.1-
pLF-N/L. pentosus induced by xylose; M: low molecular weight protein marker 
 
Fig. 3. Identification of the protein expressed in Lactobacillus pentosus by Western blot. Lane 1: 
pPG612.1/L. pentosus induced by xylose; lane 2: recombinant strain pPG612.1-pLF-N/L. pentosus 
induced by xylose; M: low molecular weight protein marker 
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Fig. 4. Identification of the induced protein in supernatants by indirect ELISA. Mouse anti-pLF  
serum and HRP-conjugated goat anti-mouse IgG were used to confirm the pLF-N protein secreted 
from pPG612.1-pLF-N/L. pentosus. The results indicated that the pLF-N protein was present in the 
supernatant of overnight culture, while it was absent in the control bacteria pPG612.1/L. pentosus. 
‘(+)’ means MRS medium supplemented with xylose to induce the expression of recombinant  
protein, while ‘(–)’ represents MRS medium without xylose 
 
The expressed recombinant pLF-N protein showed antibacterial activity in 
the antibacterial activity assay. The time dynamic curve method indicated that 
the induced supernatant of pPG612.1-pLF-N/Lactobacillus pentosus had an 
growth-inhibiting effect on Gram-positive bacteria Staphylococcus aureus strain 
CVCC26003 and Bacillus subtilis strain CVCC63501 and on Gram-negative 
bacteria Escherichia coli strain CVCC10141, Salmonella enterica ssp. enterica 
Choleraesuis strain CVCC79102, while it did not inhibit the growth of Lactoba-
cillus casei strain ATCC393 (Fig. 5). 
Mouse sera were was collected on days 0, 7, 14, 21, 28, 35 and 42. Sam-
ples were stored at –20 °C until tested for specific anti-ADV antibodies by 
ELISA. IgG antibody levels to porcine ADV [expressed as optical density (OD) 
units] were significantly higher in the pPG612.1-pLF-N/L. pentosus group than 
in the control (PBS and L. pentosus) groups at 7 and 21 days (P < 0.01) and at 
day 14 (P < 0.05). Differences in antibody levels between the groups were not 
significant at days 28, 35 and 42, but IgG levels were somewhat higher in the 
pPG612.1-pLF-N/L. pentosus group than in the L. pentosus and PBS groups 
(Fig. 6), indicating that oral administration of pPG612.1-pLF-N/L. pentosus had 
an enhancing effect on humoral immunity induced in mice by a commercial at-
tenuated porcine ADV vaccine. 
 
Discussion 
Lactoferrin has many biological functions, and it is particularly well known 
for its antimicrobial activity. LF is a broad-spectrum antimicrobial agent and has 
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Fig. 5. The antimicrobial activity of recombinant porcine lactoferrin against the tested bacteria.  
a: Bacillus subtilis strain CVCC63501; b: Staphylococcus aureus strain CVCC26003;  
c: Escherichia coli strain CVCC10141; d: Salmonella enterica ssp. enterica Choleraesuis strain 
CVCC79102; e: Lactobacillus casei strain ATCC393 
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Fig. 6. IgG levels against Aujeszky’s disease virus in the serum of mice. Mouse serum was  
collected on days 0, 7, 14, 21, 28, 35 and 42. Compared to the control PBS and L. pentosus groups, 
IgG antibody levels to Aujeszky’s disease virus [expressed as optical density (OD) units] in the 
group orally treated with pPG612.1-pLF-N/L. pentosus were significantly higher on days 7 and 21 
(P < 0.01) and on day 14 (P < 0.05). Although on days 28, 35 and 42 there was no significant  
difference in antibody levels between the groups, the IgG levels were somewhat higher in the 
pPG612.1-pLF-N/L. pentosus group than in the L. pentosus and PBS groups 
 
It can also maintain the balance of the gut flora and promote the growth of bene-
ficial bacteria in the intestine of animals. Many studies have shown that the bio-
logical properties of LF are closely associated with the N-lobe (Mishra et al., 
2013). In this study, the N-terminal of porcine lactoferrin gene was expressed us-
ing a Lactobacillus secretion expression vector and the resulting recombinant 
protein exhibited antibacterial activity against Escherichia coli, Salmonella en-
terica ssp. enterica Choleraesuis, Bacillus subtilis and Staphylococcus aureus 
but not against Lactobacillus casei. The study showed that the recombinant strain 
shows a clear inhibitory effect not only on Gram-negative bacteria such as E. coli 
and Salmonella but also on Gram-positive bacteria such as Staphylococcus 
aureus and Bacillus subtilis. It inhibits Gram-positive bacteria slightly stronger 
than Gram-negative bacteria, but it has no inhibitory effect on Lactobacillus ca-
sei. In the pre-trial, a natural porcine lactoferrin (purchased from Sigma-Aldrich 
Co, St. Louis, MO, USA) was tested against Lactobacillus casei, L. plantarum 
and L. pentosus. The results indicated that lactoferrin did not influence the 
growth of these three strains. Earlier research (Casey et al., 2007) showed that L. 
pentosus inhibits the growth and reproduction of harmful bacteria and promotes 
the colonisation of the intestine by beneficial bacteria, thus contributing to the 
prevention of diarrhoea. As a result, L. pentosus was selected as the host strain to 
deliver the porcine lactoferrin. 
Many studies have shown that lactoferrin has immunoregulatory function 
and acts as an immunological adjuvant (Hwang et al., 2007; Wilk et al., 2007; 
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Hwang et al., 2009; Welsh et al., 2010; Allaire et al., 2015; Sherman et al., 
2015). Lactic acid bacteria are generally regarded as food-grade microorganisms, 
which can survive in the intestinal tract of animals and have the potential to ex-
press foreign genes. In this study, lactic acid bacteria were used as an expression 
system to produce porcine lactoferrin. The resulting product was orally adminis-
tered to mice immunised with a porcine ADV vaccine to explore its ability to en-
hance the effect of the vaccine. 
The results obtained by periodic determination of serum IgG antibody lev-
els indicated that the orally administered recombinant L. pentosus elevated ADV 
antibody levels as compared to the L. pentosus control group and the PBS group, 
suggesting that lactoferrin can enhance vaccination-induced humoral immunity 
to a certain extent. A significant increase in antibody level was found in the 
group orally administered recombinant porcine lactoferrin; thus, the immuno-
modulatory function of lactoferrin was demonstrated. Lactoferrin possesses im-
mune-enhancing effects, which may be related to its participation in immu-
noregulation. LF itself can induce a humoral immune response and affect many 
components of the immune system by influencing the maturation of T and B 
cells and the proliferation of lymphocytes and by regulating iron levels in mono-
cytes and macrophages. It can also be used with single-core white blood cells, 
neutrophils, lymphocytes or macrophages to enhance the killing ability of natural 
killer cells (Moriuchi and Moriuchi, 2006; Chen et al., 2008; Chen et al., 2011). 
The administration of rPLF significantly increased the length of intestinal villi in 
chicken and enhanced the expression of IFN-gamma and IL-12 in chicken T 
lymphocytes. It has been reported that rPLF enhances cell-mediated immunity 
and augments the effectiveness of infectious bursal disease (IBD) vaccination in 
chicken (Hung et al., 2010). This suggests that lactoferrin impacts nonspecific 
and specific immunity by promoting both the humoral and the cell-mediated 
immune response. 
In conclusion, we have successfully constructed a probiotic L. pentosus 
expression system producing porcine lactoferrin. The recombinant strain 
pPG612.1-pLF-N/L. pentosus has the ability to secrete porcine lactoferrin and is 
able to inhibit the tested bacteria. The oral administration of recombinant L. pen-
tosus strain expressing porcine lactoferrin was found to elevate IgG antibody 
levels in mice immunised with an attenuated porcine Aujeszky’s disease virus 
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